Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A whole deal based on fragments
May 2019
SHARING OPTIONS:

SAFFRON WALDEN, U.K. & BASEL, Switzerland—March saw Domainex Ltd and SpiroChem AG announce a strategic fragment drug discovery collaboration that the partners intend to co-promote globally. Per the agreement, Domainex will boost its fragment collection with a diverse set of SpiroChem fragments that the former will screen with its FragmentBuilder platform. The fragments from SpiroChem will offer unique chemical diversity, specifically in terms of 3D chemotypes. The partners will work together to provide hit expansion services on the resulting fragment hits for clients in a seamless approach.
 
Thomas Fessard, CEO of SpiroChem, commented in part that “Fragment-based lead discovery has demonstrated its strength in delivering new leads for drug targets over the past few years, and we have seen a booming demand for our fragment collections.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.